Quantum Genesis AI Corp. (OTC: QGAI), a biotechnology company specializing in enzyme engineering, molecular modeling, and biocatalysis, has issued a clarification regarding its research activities and intellectual property. The company seeks to distinguish its own work from that of Quantumzyme LLP, a separate entity based in Bengaluru, India, which is not affiliated with Quantum Genesis AI.
The clarification addresses prior press releases from November 5, 2025, and February 12, 2026, which referenced scientific publications in the company's field. Those publications identified Quantumzyme LLP and reflected the affiliations of researchers at the time of submission. Quantum Genesis AI now clarifies that those publications pertain to the broader field of enzyme engineering and are not direct outputs of the company.
According to the statement, the company's Chief Executive Officer, Naveen Kulkarni, transferred certain intellectual property, know-how, and methodologies to Quantum Genesis AI pursuant to an Asset Purchase Agreement dated February 21, 2023. A subsequent confirmatory assignment, as disclosed in a Form 8-K filed on April 29, 2026, further solidified these rights. The company believes that any research conducted by Mr. Kulkarni, whether directly or through Quantumzyme LLP, that relies on the transferred technology platform falls within the scope of the company's intellectual property.
This announcement serves to clarify ownership of technology and methodologies used in the company's core business. The company's prior disclosures regarding scientific publications were based on its ownership of the relevant intellectual property. For more information, visit qgaicorp.com and the company's profile on OTC Markets.
The clarification is important for investors and stakeholders as it delineates the boundaries of Quantum Genesis AI's intellectual property and its relationship with external entities. It underscores the company's commitment to transparency and accurate disclosure of its technological assets.
